Cargando…
The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression
One of the main obstacles of conventional anticancer therapy is the toxicity of chemotherapeutics to normal tissues. So far, clinical approaches that aim to specifically reduce chemotherapy-mediated toxicities are rare. Recently, a number of studies have demonstrated that herbal extracts derived fro...
Autores principales: | Becker, M S, Schmezer, P, Breuer, R, Haas, S F, Essers, M A, Krammer, P H, Li-Weber, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040689/ https://www.ncbi.nlm.nih.gov/pubmed/24434508 http://dx.doi.org/10.1038/cddis.2013.528 |
Ejemplares similares
-
The anticancer phytochemical rocaglamide inhibits Rho GTPase activity and cancer cell migration
por: Becker, Michael S., et al.
Publicado: (2016) -
Progress in the Total Synthesis of Rocaglamide
por: Cai, Xiao-hua, et al.
Publicado: (2011) -
In silico study on the Hepatitis E virus RNA Helicase and its inhibition by silvestrol, rocaglamide and other flavagline compounds
por: Pedroni, Lorenzo, et al.
Publicado: (2022) -
Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs
por: Nalli, Ancy D., et al.
Publicado: (2018) -
Rocaglamide-A Potentiates Osteoblast Differentiation by Inhibiting NF-κB Signaling
por: Li, Aiguo, et al.
Publicado: (2015)